Herein, we conducted a retrospective clinical investigation to confirm that IDH1-mutant glioma patients indeed exhibited improved prognoses, greater responsiveness to TMZ treatment, and elevations of D-2HG in comparison to those with IDH1 wild-type gliomas. The gene discussed is IDH1; the disease is glioma.